Michael Myers bought $250k of QNRX
Chief Executive Officer at Quoin Pharmaceuticals, Ltd.. 555,556 shares at an average of $0.45, traded Dec 23, 2024, filed Dec 27, 2024.
Score components
- +25RoleCEO
- +13Trade size$250k at market
- +10Relative to holdingsHoldings up 1176%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -30.7%, 3m -56.0%, 6m -51.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-132188, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | POpen-market purchase Ordinary Shares | +555,556 | $0.45 | $250k | 602,808 | Dec 27, 2024 |
| Dec 23, 2024 | POpen-market purchase Series F Warrants (right to buy)derivative | +555,556 | - | - | 555,556 | Dec 27, 2024 |
| Dec 23, 2024 | POpen-market purchase Series G Warrants (right to buy)derivative | +555,556 | - | - | 555,556 | Dec 27, 2024 |
Related signals
Other insiders at Quoin Pharmaceuticals, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $100k 20,490 shares | +119% | |
| 38Weak | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $30k 6,146 shares | +18% | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Sally Bridget Lawlor Chief Financial Officer | $50k 10,244 shares | +2328% | |
| 60Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $100k 20,490 shares | +119% | |
| 44Moderate | QNRXbuy Quoin Pharmaceuticals, Ltd. | Dennis Langer director | $129k 15,152 shares | first purchase | |
| 58Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $250k 555,556 shares | +1180% | |
| 46Moderate | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $45k 100,000 shares | first purchase | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Gordon Dunn Chief Financial Officer | $55k 122,221 shares | +424% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.